Tesamorelin
Also known as: Egrifta, Egrifta SV, Egrifta WR, Tesamorelin acetate, TH9507
Classification
Peptide
Regulatory Status
unknown
Overview
Tesamorelin is a synthetic analogue of human growth hormone-releasing hormone (GHRH) that stimulates the pituitary to release endogenous growth hormone, in turn increasing IGF-1; its molecular formula is C221H366N72O67S (PubChem CID 16137828).
Evidence and limitations
Human/preclinical evidence breakdown is not available in this record.
Expansion-batch evidence packet requires human review before publication. | PubMed/PMC primary-source pages (including the GHRH/cognition trial and an integrase-inhibitor-era tesamorelin efficacy/safety study) were blocked by CAPTCHA/bot-verification this session and could not be independently quoted; re-fetch required. | Full DOSAGE AND ADMINISTRATION label text was not captured due to a WebFetch rate limit; re-pull from the label PDF or DailyMed before publishing any dose-context claim. | CAS/UNII/RxNorm/DrugBank/ChEMBL identifiers not yet resolved from structured databases. | Cognitive-benefit marketing claim needs independent verification against the primary Baker et al. GHRH cognition trial before the evidence-gap claim can be closed or upgraded. | Compiled draft requires human review before publication.
Pathways
Tesamorelin is a synthetic analogue of human growth hormone-releasing hormone (GHRH) that stimulates the pituitary to release endogenous growth hormone, in turn increasing IGF-1; its molecular formula is C221H366N72O67S (PubChem CID 16137828).
Sources
Educational reference only — not medical advice.